| 14.4 0 (0%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.45  |
1-year : | 18.06 |
| Resists | First : | 14.94 |
Second : | 15.47 |
| Pivot price | 14.52 |
|||
| Supports | First : | 14.1 |
Second : | 11.73 |
| MAs | MA(5) : | 14.32  |
MA(20) : | 14.54 |
| MA(100) : | 14.32 |
MA(250) : | 11.28 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 17.9 |
D(3) : | 13.7 |
| RSI | RSI(14): 43.1 | |||
| 52-week | High : | 16.54 | Low : | 6.55 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AUPH ] has closed above bottom band by 39.8%. Bollinger Bands are 41.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.49 - 14.56 | 14.56 - 14.62 |
| Low: | 13.9 - 14 | 14 - 14.08 |
| Close: | 14.26 - 14.41 | 14.41 - 14.53 |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Sat, 21 Feb 2026
Jupiter Asset Management Ltd. Has $9.10 Million Stake in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Wed, 11 Feb 2026
83,780 Shares in Aurinia Pharmaceuticals Inc $AUPH Purchased by Navellier & Associates Inc. - MarketBeat
Sat, 07 Feb 2026
Investing in Aurinia Pharmaceuticals (NASDAQ:AUPH) a year ago would have delivered you a 80% gain - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 132 (M) |
| Shares Float | 128 (M) |
| Held by Insiders | 6.8 (%) |
| Held by Institutions | 50.7 (%) |
| Shares Short | 8,730 (K) |
| Shares Short P.Month | 8,390 (K) |
| EPS | 0.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.76 |
| Profit Margin | 29.2 % |
| Operating Margin | 40.4 % |
| Return on Assets (ttm) | 9.4 % |
| Return on Equity (ttm) | 20.6 % |
| Qtrly Rev. Growth | 8.3 % |
| Gross Profit (p.s.) | 1.61 |
| Sales Per Share | 2.01 |
| EBITDA (p.s.) | 0.76 |
| Qtrly Earnings Growth | 130 % |
| Operating Cash Flow | 120 (M) |
| Levered Free Cash Flow | 85 (M) |
| PE Ratio | 25.71 |
| PEG Ratio | 0 |
| Price to Book value | 5.19 |
| Price to Sales | 7.14 |
| Price to Cash Flow | 15.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|